-
Exemestane, sold
under the
brand name
Aromasin among others, is a
medication used to
treat breast cancer. It is a
member of the
class of antiestrogens...
- (everolimus) to
exemestane therapy against advanced breast cancer can
significantly improve progression-free
survival compared with
exemestane therapy alone...
-
exemestane.
Exemestane went
through clinical trials in the 1990s and
received FDA
approval in 1999,
marketed as Aromasin.
Indication for
exemestane is...
-
approved to
treat breast cancer:
Irreversible steroidal inhibitors, such as
exemestane (Aromasin),
forms a
permanent and
deactivating bond with the aromatase...
-
gynecomastia in males.
Aromatase inhibitors, such as anastrozole, letrozole,
exemestane, etc., can help to
prevent the
subsequent estrogenic activity of testosterone...
-
aromatase inhibitors,
including anastrozole, letrozole, aminoglutethimide,
exemestane, formestane, and
testolactone are banned.
Selective estrogen receptor...
-
nisoldipine (Sular) and
nitrendipine (Bayotensin)
Erlotinib (Tarceva)
Exemestane, aromasin, and by
extension all estrogen-like
compounds and aromatase...
- (INN)
Exblifep Excede Excedrin Excenel Excenel RTU EZ
Exelderm Exelon exemestane (INN)
exenatide (USAN)
exepanol (INN)
Exforge Exforge HCT
Exidine exifone...
-
other third generation aromatase inhibitors anastrozole,
letrozole and
exemestane. Goss PE (1998). "Pre-clinical and
clinical review of vorozole, a new...
- Second-generation:
Fadrozole Formestane Third-generation:
Anastrozole Exemestane Letrozole Antigonadotropins Androgens/anabolic
steroids (e.g., testosterone...
